PRNewsWire
07 Oct 2025, 12:01 UTC · 49w ago
Verdict
Headline takes no side. We score AEMD +0.40 across three claims — moderately bullish.
+0.40moderately bullish
More positive than 64% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Aethlon Medical observed directional changes in extracellular vesicles, microRNAs, and lymphocytes in the initial three-patient cohort following a single Hemopurifier treatment.
So whatPositive early biological data for a micro-cap biotech provides a speculative boost, but the impact is strictly limited by the extremely small sample size (n=3) and the lack of clinical efficacy correlation.
More positive than 71% of claims this week
The company explicitly states it cannot make any correlation between the observed biomarker changes and clinical efficacy, which can only be determined in a larger PMA trial.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 69% of claims this week
The Hemopurifier holds U.S. FDA Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard-of-care therapy.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
The company reported encouraging preliminary observations regarding its Hemopurifier in an oncology clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
−84.1%
Price is moving against the score
$6.16 vs $38.65 close before publication (Oct 6) · not market-adjusted
AEMD chart →
